Oncolytics Biotech (ONCY) Exchange Rate Effect (2009 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Exchange Rate Effect of $122106.0 for Q4 2025, down 80.1% year-over-year from $613482.7 in Q4 2024, and down 48.45% quarter-over-quarter from $236883.0 in Q3 2025.
Oncolytics Biotech (ONCY) Exchange Rate Effect (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Exchange Rate Effect for 17 consecutive years, with $122106.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Exchange Rate Effect fell 80.1% year-over-year to $122106.0; the TTM figure through Dec 2025 stood at $296112.8 (down 74.55% YoY), while the FY2025 annual figure was $121000.0, up 141.87% from the prior year.
- Exchange Rate Effect retreated to $122106.0 in Q4 2025 per ONCY's latest filing, from $236883.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $1.4 million in Q3 2022 and bottomed at -$602028.0 in Q2 2021.
- Historically, Exchange Rate Effect has averaged $100149.7 across 5 years, with a median of $24333.4 in 2025.
- Annual changes were most pronounced in 2021 — Exchange Rate Effect soared 909.09% — and 2025, when it slumped 332.33%.
- Oncolytics Biotech's Exchange Rate Effect stood at -$288757.7 in 2021, then advanced by 28.56% to -$206276.8 in 2022, then slumped by 143.57% to -$502422.3 in 2023, then soared by 222.1% to $613482.7 in 2024, then sank by 80.1% to $122106.0 in 2025.
- Business Quant data shows ONCY's Exchange Rate Effect at $122106.0 in Q4 2025, $236883.0 in Q3 2025, and -$417871.5 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 10 | Oncolytics Biotech | 99.04 Mn | 99.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 122,106.00 |
| Dec 31, 2025 | 122,106.00 |
| Sep 30, 2025 | 236,883.01 |
| Sep 30, 2025 | 236,883.01 |
| Jun 30, 2025 | -417,871.54 |
| Jun 30, 2025 | -417,871.54 |
| Mar 31, 2025 | -21,604.41 |
| Mar 31, 2025 | -21,604.41 |
| Dec 31, 2024 | 613,482.71 |
| Dec 31, 2024 | 613,482.71 |
| Sep 30, 2024 | -157,606.48 |
| Sep 30, 2024 | -157,606.48 |
| Jun 30, 2024 | 179,860.57 |
| Jun 30, 2024 | 179,860.57 |
| Mar 31, 2024 | 527,642.49 |
| Mar 31, 2024 | 527,642.49 |
| Dec 31, 2023 | -502,422.30 |
| Dec 31, 2023 | -502,422.30 |
| Sep 30, 2023 | 325,225.68 |
| Sep 30, 2023 | 325,225.68 |